Business Description
Lexaria Bioscience Corp
NAICS : 325412
SIC : 2834
Share Class Description:
LEXXW: Warrants (11/01/2026)Total Employee Number:
7Description
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 41.58 | |||||
Equity-to-Asset | 0.99 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -3.13 | |||||
Beneish M-Score | -3.98 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.3 | |||||
3-Year EBITDA Growth Rate | 16.1 | |||||
3-Year EPS without NRI Growth Rate | 16 | |||||
3-Year FCF Growth Rate | 12 | |||||
3-Year Book Growth Rate | -51.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -77.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 10.61 | |||||
Quick Ratio | 10.61 | |||||
Cash Ratio | 9.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -48.6 | |||||
Shareholder Yield % | -41.82 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -3973.71 | |||||
Net Margin % | -3985.57 | |||||
EBITDA Margin % | -3934.02 | |||||
ROE % | -155.92 | |||||
ROA % | -136.92 | |||||
ROIC % | -901.01 | |||||
3-Year ROIIC % | 677.22 | |||||
ROC (Joel Greenblatt) % | -1948.69 | |||||
ROCE % | -166.15 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 64.76 | |||||
PB Ratio | 3.27 | |||||
EV-to-EBIT | -1.5 | |||||
EV-to-EBITDA | -1.52 | |||||
EV-to-Revenue | 59.76 | |||||
EV-to-FCF | -1.54 | |||||
Earnings Yield (Greenblatt) % | -66.67 | |||||
FCF Yield % | -48.51 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LEXXW
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexaria Bioscience Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | - | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | - | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0 - 5.19 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexaria Bioscience Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexaria Bioscience Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2027-01-27 13:00 | In 141 days | ||
| First quarter earnings results for 2027 | 2027-01-13 | In 126 days | ||
| Annual report for 2026 | 2026-11-26 | In 78 days | ||
| the 28th Annual H.C. Wainwright Global Investment Conference | 2026-09-11 07:00 | In 3 days | ||
| Third quarter earnings results for 2026 | 2026-07-13 | -- | ||
| Second quarter earnings results for 2026 | 2026-04-13 | -- | ||
| General meeting for 2025 | 2026-01-27 13:00 | -- | ||
| First quarter earnings results for 2026 | 2026-01-13 | -- | ||
| Annual report for 2025 | 2025-11-26 | -- | ||
| Third quarter earnings results for 2025 | 2025-07-14 | -- |
Show
Entries
Lexaria Bioscience Corp Frequently Asked Questions
What is Lexaria Bioscience Corp(LEXXW)'s stock price today?
The current price of LEXXW is $0.00. The 52 week high of LEXXW is $5.19 and 52 week low is $0.00.
When is next earnings date of Lexaria Bioscience Corp(LEXXW)?
The next earnings date of Lexaria Bioscience Corp(LEXXW) is 2026-10-13 Est..
Does Lexaria Bioscience Corp(LEXXW) pay dividends? If so, how much?
Lexaria Bioscience Corp(LEXXW) does not pay dividend.
Press Release
Articles on Lexaria Bioscience Corp
No articles.
Headlines
See More- 1
Sep 01, 2026
Lexaria receives $2.6M R&D tax rebate from Australian Tax Office; shares up over 14%
Seeking Alpha • 9:52am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers